Westchester Capital Management (New York)’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Westchester Capital Management (New York)’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55K	Hold	500,000	–	–	﹤0.01%	265
2026 Q1	$27.6K	Hold	500,000	–	–	﹤0.01%	281
2025 Q4	$79K	Hold	500,000	–	–	﹤0.01%	252
2025 Q3	$109K	Hold	500,000	–	–	0.01%	209
2025 Q2	$62.5K	Buy	+500,000	New	+$64.3K	﹤0.01%	169

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Westchester Capital Management (New York)'s DMAAR Position: Q2 2026 in Review

Westchester Capital Management (New York) held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 500,000 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Westchester Capital Management (New York) first reported a position in DMAAR in Q2 2025 and has held it in 5 quarters since. The position peaked at $109K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Westchester Capital Management (New York) held 500,000 shares of Drugs Made In America Acquisition Corp Rights worth $55K as of Q2 2026.
Westchester Capital Management (New York) left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Westchester Capital Management (New York)'s portfolio in Q2 2026, its #265 holding.
Westchester Capital Management (New York) first reported a position in Drugs Made In America Acquisition Corp Rights in Q2 2025 and has held it in 5 quarters since.
Westchester Capital Management (New York)'s Drugs Made In America Acquisition Corp Rights position peaked at $109K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Westchester Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.